Navigation Links
Sihuan Pharmaceutical Announces 2013 Interim Results
Date:8/26/2013

s are expected to be launched starting from 2015.

In view of strong future growth, the Company will continue to enhance its nationwide distribution network and sales and marketing capabilities. Meanwhile, the Company will continue to exploring opportunities and enhancing its R&D capability by continuous investment in order to sustain healthy and sustainable growth.

Dr. Che concluded, "Despite increasingly rigid demand in the pharmaceutical industry, changes in policies and intense market competition continue to pose challenges to the industry's development. As an innovative pharmaceutical company which focuses on exclusive and proprietary products, Sihuan Pharmaceutical has sharpened its advantage in resources amidst the challenging market environment. Backed by its outstanding capabilities in sales and marketing, R&D and resource integration, Sihuan Pharmaceutical is poised to capitalize on the trend of industry consolidation and to achieve sustainable development going forward. I am highly confident in Sihuan's 2013 full year operating results and the Company's future development, and firmly believe that it will welcome a new era of development by entering into a steady growth trajectory. We are taking concrete steps towards our goal of becoming the most competitive Chinese pharmaceutical company." 

About Sihuan Pharmaceutical Holdings Group Ltd.Founded in 2001, Sihuan Pharmaceutical Holdings Group Ltd. is a leading Chinese pharmaceutical corporation and the largest cardio-cerebral vascular drug franchise in China's prescription drug market by market share. The Company also became the third largest pharmaceutical company in terms of hospital purchase in the Chinese prescription drug market in the first half of 2013. The success of the Group can be attributed to its differentiated and proven sales and marketing model, extensive nationwide distribution network, young and diversified product portfolio, and
'/>"/>

SOURCE Sihuan Pharmaceutical Holdings Group Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
2. Sihuan Pharmaceutical Announces 2012 Annual Results
3. State Food and Drug Administration Grants Approval to Sihuan Pharmaceutical for Clinical Trial of Innovative Drug -- Pinoxacin Hydrochloride
4. Sihuan Pharmaceutical Collaborates with NeuroVive to Develop Two Innovative Cardio-cerebral Vascular Products in China
5. Sihuans First-to-market Generic Drug Roxatidine Receives New Drug Certificate and Approval for Production
6. Sihuan Pharmaceutical Announces 2012 Interim Results
7. Sihuans First-to-market Generic Drug Roxatidine Passes On-site Inspection for Drug Registration Conducted by the Chinese State Food and Drug Administration
8. Immune Pharmaceuticals Completes Merger with EpiCept Corporation
9. Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
10. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
11. Par Pharmaceutical Receives Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 IRIDEX Corporation (NASDAQ: ... James H. Mackaness is scheduled to make an investor ... at 2:55 p.m. Eastern Time on Wednesday, September 3, in ... of the investor presentation will be available in the Investors ... About IRIDEX IRIDEX Corporation was founded ...
(Date:8/27/2014)... Calif. , Aug. 27, 2014 Asterias ... U.S. Food and Drug Administration (FDA) to initiate a ... patients with complete cervical spinal cord injury.  The approved ... clinical study of the product, and is designed to ... in patients with complete cervical spinal cord injuries, the ...
(Date:8/26/2014)... Aug. 26, 2014  Kewaunee Scientific Corporation (Nasdaq: ... quarter ended July 31, 2014. Sales for ... $32,003,000 in the first quarter last year. Net earnings ... share, as compared to net earnings of $1,587,000, or ... the prior year. However, both sales and earnings in ...
Breaking Medicine Technology:Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5Kewaunee Scientific Reports Results for First Quarter 2Kewaunee Scientific Reports Results for First Quarter 3Kewaunee Scientific Reports Results for First Quarter 4Kewaunee Scientific Reports Results for First Quarter 5Kewaunee Scientific Reports Results for First Quarter 6
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) ... two fidaxomicin Phase 3 trials in patients with ... Meeting of the Infectious Disease Society of America (IDSA) ... investigator Derrick Crook, M.D., of the University of Oxford, ...
... leading home health care and hospice company (Nasdaq: AMED ... home care in this week,s issue of the New England Journal ... Advisory Board. Titled, "Why Health Care is Going ... home care as an increasingly crucial component of America,s health care ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 2Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 3Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 4Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 5Media Statement From Amedisys on Dr. Steven H. Landers' NEJM Commentary on the Future of Home Care 2
(Date:8/27/2014)... to market research report, “Variable Frequency Drives Market by ... High), Voltage (Low & Medium), Application (Pump, Fan, Compressor, ... & Forecast to 2019” defines and segments the global ... of the market size. The variable frequency drives market ... to $22.73 billion by 2019, with a CAGR of ...
(Date:8/27/2014)... 27, 2014 Specialty Technical Publishers (STP) ... International Audit Protocol Consortium (IAPC) EHS audit protocol for ... around the world use IAPC EHS audit protocols to ... rapidly collect, share, archive, and export audit findings in ... are prepared by AECOM in partnership with STP and ...
(Date:8/27/2014)... Main Street Dental Team ( MainStreetDentalTeam.com ), ... how long a toothbrush can be used before it has ... teeth and gums. , “Replacing a toothbrush is something that ... Dr. Harvey Schwartz, owner of Main Street Dental Team. “Using ... months." , Dr. Schwartz explains that what’s important to keep ...
(Date:8/27/2014)... Top10inaction, a professional website reveals the best ... by name brands such as Apple, Samsung, Sony, Blackberry ... means a lot more than just a device of ... surf the internet with their little toys. And just ... to choose a right smartphone has become a dilemma. ...
(Date:8/27/2014)... DC (PRWEB) August 27, 2014 ... Diplomat University were announced as the winners of ... August issue of Atlantic Information Services, Inc.’s ... penned by the company’s founder and Principal Consultant ... were commended for meeting the true definition of ...
Breaking Medicine News(10 mins):Health News:Variable Frequency Drives Market Worth $22.73 Billion by 2019 – New Report by MarketsandMarkets 2Health News:Specialty Technical Publishers and AECOM Publish Environmental, Health & Safety (EHS) Audit Protocol for Brazil (and the State of São Paulo) 2Health News:Specialty Technical Publishers and AECOM Publish Environmental, Health & Safety (EHS) Audit Protocol for Brazil (and the State of São Paulo) 3Health News:Specialty Technical Publishers and AECOM Publish Environmental, Health & Safety (EHS) Audit Protocol for Brazil (and the State of São Paulo) 4Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Advises on the Best Time to Replace a Toothbrush 2Health News:Best Smartphones 2014 Revealed by Top10InAction.com 2Health News:Specialty Pharmacy Solutions Founder Reveals Winners of Innovation Competition in August Issue of AIS Newsletter 2Health News:Specialty Pharmacy Solutions Founder Reveals Winners of Innovation Competition in August Issue of AIS Newsletter 3
... Will Highlight Hurdles To Government Oversight & Gaining ... ... Without an improved,governance structure, the benefits of nanotechnology may be difficult ... David Rejeski, director of the Project on Emerging,Nanotechnologies (PEN). Rejeski testifies ...
... 10,000 University of California RNs to ... Bargain Over Improved Patient Safety, OAKLAND, ... the California Nurses Association/National Nurses Organizing,Committee today won a major ... nurses it represents to strike, and to,bargain over improved staffing ...
... Fla., April 22 PainCare Holdings,Inc. (Amex: PRZ ... services, today announced that it received a letter from ... notifying the Company that,its delay in filing its Form ... a failure to comply with the continued listing standards,set ...
... 22 Cardica, Inc.,(Nasdaq: CRDC ) today announced ... quarter ended March 31, 2008, on Tuesday, April 29, ... host a,conference call at 4:30 p.m. Eastern Time to ... company,s business., Conference Call Details, To access ...
... (Nasdaq: UAHC ) today announced that the ... Tennessee, Bureau of TennCare,(,TennCare,), today publicly disclosed its ... organizations, not including the company,s,subsidiary, UAHC Health Plan ... of TennCare,s selection process pursuant to its Request ...
... use of cisplatin no better than standard treatment, researchers ... Compared to the standard treatment regimen for anal canal ... other treatments didn,t improve disease-free survival and resulted in ... study. , Currently, the preferred primary therapy for patients ...
Cached Medicine News:Health News:Improved Governance Needed To Realize Nanotech's Benefits 2Health News:CNA/NNOC Wins Key Legal Decision Protecting Right of Public Employees to Strike 2Health News:PainCare Receives Notices From American Stock Exchange 2Health News:PainCare Receives Notices From American Stock Exchange 3Health News:PainCare Receives Notices From American Stock Exchange 4Health News:Cardica to Announce Fiscal 2008 Third Quarter Financial Results on Tuesday, April 29, 2008 2Health News:United American Healthcare Corporation Provides Update on TennCare RFP Awards 2Health News:New Anal Cancer Therapy Fails to Improve Outcomes 2
Inquire...
... damaged fiber optics reduce the light output to ... in the optical clarity that is so vital. ... essential to prevent further damage and more extensive ... can inspect your cables for you at no ...
Inquire...
... inspects your equipment upon arrival. Our technician then ... provides you with a thorough customer quote. We ... tight budget so well help you prioritize repairs. ... begins., , ISI uses only OEM or widely ...
Medicine Products: